

Thu 30th March 2023



shown to enhance the absorption of iron when taken together.

For use when iron deficiency or iron deficiency anaemia has been diagnosed by your doctor and a therapeutic iron supplement is recommended. Always read the label and follow the directions for use. If symptoms persist, worsen or change unexpectedly, talk to your health professional. *Vitamin C has been

Petrus PHARMACEUTICALS

Today's issue of *PD*

Pharmacy Daily today features five pages of news, including our new Beauty & Wellness feature plus full pages from:

- Willach
- Glucojel

Meet your needs

WILLACH has delivered over 1,000 dispensary automation solutions in the past 15 years. Learn more on how you too can optimise efficiency and reduce errors.

See more on page six.

Beauty & Wellness

WE HAVE launched our dedicated beauty and wellness page for all pharmacy staff. We'd love to hear your feedback, and to submit news for the page, CLICK HERE.

Measles alert

NSW Health is alerting about one case of measles after a Western Sydney infant diagnosed with the infection spent time on Mon 27 Mar at:

- The Children's Hospital at Westmead emergency department waiting room between 12-9:30pm.
- Argyle Street Medical Centre, Parramatta between 9:15-10am.
- Westfield Parramatta between 9:00-10am.

PSA calls for Qld Govt to expand vax

THE Pharmaceutical Society of Australia (PSA) has called on the Queensland Government to end differences in authorities across jurisdictions to allow pharmacists to provide a wider range of vaccination services to Queenslanders in more healthcare settings.

PSA Queensland President, Shane MacDonald and State Manager, Nicole Floyd have met with the Hon Yvette D'Ath MP, Minister for Health and Ambulance Services (pictured) to advocate for the removal of the regulatory barriers preventing pharmacists providing more vaccinations services to Queenslanders.

"Pharmacists have been administering vaccines in Queensland since 2014.

"We are an important part of the immunising workforce," MacDonald said.

"Our vaccination authorisation in Queensland has fallen behind other states and territories, which impacts the accessibility of preventative healthcare for Queenslanders.

"The Queensland Government needs to urgently improve the legislative authority, allowing pharmacists to administer more vaccines to more patients.

"Although new vaccines are included in the North Queensland Scope of Practice Pilot, PSA believes that pharmacists have already proven themselves as quality and safe vaccinators and all of Queensland deserves immediate access to these vaccines.

"It makes no sense that a patient



in Qld cannot access a vaccine for Human Papillomavirus (HPV) from their local pharmacist, but a patient in ACT, NSW, Victoria, and Western Australia can.

"The same can be said for Herpes Zoster and Hepatitis B vaccines.

"Frankly, the differences in authorities across jurisdictions is confusing for patients and confusing for the workforce (especially locums).

"If all vaccines were authorised in Qld, pharmacists could support catch-up strategies and reduce missed opportunities for vaccinations due to their unique accessibility.

"This is particularly important post COVID-19 due to the disruption in access to health services during the pandemic," explained MacDonald.

PSA has also called on the Queensland Government to allow community pharmacists to administer vaccines in outreach programs (such as schools, aged care, and workplaces), as well as pharmacists working in general practice, Aboriginal Community Controlled Health Organisations and aged care.

The current authorisation for these settings is only temporary and expires on 29 Apr.

"The location where the vaccine is administered does not alter the competency and skill of the pharmacist.

"We need qualified pharmacists to be able to administer vaccines wherever there is a patient need," MacDonald concluded.



24/7 monitoring and response by an expert Cyber Security Operations Centre

A plan for every pharmacy Call 1800 888 828




Our Essential Range

Created to support general well-being whilst helping you to obtain enough essential nutrients to maintain or improve your health.

Download an order form

և UltraNature.com.au







Thu 30th March 2023



Take the survey

COMMUNITY Pharmacists are invited to share their views **HERE** with Uni of Tasmania researchers on implementing a patient self-administered screening tool for identifying medication-related problems.





Renewed focus on best patient care

TERRYWHITE Chemmart hosted a series of Academy Live and Masterclass Forum training events this month to over 450 members, aimed at providing industry leading education to pharmacists and pharmacy assistants from across Australia.

A key focus of the programs is to launch the updated TerryWhite Chemmart customer experience framework, 'Smile and Care'.

This was developed with customer experience expert and consumer futurist Amanda Stevens to support the rollout of the new TerryWhite Chemmart brand's customer promise - Dedicated to Care (*PD* 28 Feb).

TerryWhite Chemmart Executive General Manager Nick Munroe says he recognises the ongoing importance of focusing on and winning every customer interaction, and the new framework aims to support pharmacists, and their teams deliver better care every day.

"At TerryWhite Chemmart we are incredibly pleased to continue

our work with Amanda to help bring our customer promise to life through the development and delivery of training for our pharmacists and pharmacy assistants," said Munroe.

The Smile and Care training program for customer experience is a blended learning product of faceto-face workshops, online learning modules and in store and retail leader meetings.

"Developing this exclusive program for the pharmacy industry has been an exciting project, working hand-in-hand with the TerryWhite Chemmart team to bring about a renewed focus on providing the best possible experience for customers has been

phenomenal," said Stevens.
The Masterclass Forum and
Academy Live programs are
designed to facilitate peer-topeer learning across a variety of
current topics, new products and
disease state focuses - helping to
build the skill and capability of
both pharmacists and pharmacy
assistants from across the network.

The program further elaborates into areas of leadership in vaccinations, the rollout of the TWC CareClinic strategy, the everchanging prescription landscape with a strong focus on the myTWC digital platform.

Speaking further about the programs, Munroe mentioned that with continual change in the pharmacy landscape, investment in education has never been more pertinent.

"With the evolvement of full scope across vaccines and other areas of practice, we have developed a learning program that is highly relevant to ensure we are delivering top quality care to every patient," Munroe concluded.





The Race is back!

Sign up patients to the app for your chance to win a share of over \$15,000!

CLICK TO REGISTER



MedAdvisor

The market-leading PI cover for Australian pharmacists

THE IRON COMPANY



pdl.org.au



Thu 30th March 2023



Flu numbers up

NEW research shows many Australians continue to remain complacent about the potential seriousness of influenza (flu), despite the significantly higher cases already reported this year.

The Department of Health data shows there have been almost 14,500 confirmed flu cases already.

The Australian Attitudes to Influenza Index, commissioned by CSL Seqirus, asked 1,017 adults aged 18 years and over about their attitudes to flu.

The results showed that one third of adults say that flu is only somewhat serious, with 14% saying it's not very, or not at all, serious.

There are also clear generational gaps with only 20% of 18 to 24-year-olds indicating flu is very serious compared with nearly 60% of those 65 years and older.

I Quit Gas campaigns to live healthier

THE Climate Council has partnered with founder of the I Quit Sugar movement Sarah Wilson to launch a new campaign sounding the alarm about the health dangers of gas in our homes.

The I Quit Gas campaign is calling on state and territory governments to help Australians say goodbye to toxic gas for good with interest free loans for switching to all-electric home appliances.

It comes as a new national poll of 1,126 Australians, commissioned by the Climate Council, shows 90% of Australians are well aware of the health dangers of tobacco and asbestos, yet only 32% are aware that gas in the home is a significant health hazard.

"I founded I Quit Sugar a decade ago to help people live healthier by cutting processed sugar out of their lives at a time when there was a pretty low level of public awareness of the links between sugar and chronic diseases.

"Now, I'm taking on gas, another



dangerous substance lurking in Aussie homes," Wilson said.

"The evidence is clear and mounting that gas stoves and heaters leak toxic gases including nitrogen dioxide into our homes, which has been linked to asthma in children

"Unfortunately, public awareness about the ticking time bombs in our homes is unacceptably low.

"Just like big tobacco and big sugar have gone to great lengths

to downplay the dangers of their products, the gas industry has spent millions trying to falsely market gas as 'natural', when it is in fact toxic and dangerous.

"As well as the health risk, gas is a fossil fuel that is rapidly worsening climate change.

"It has no place in our kitchens and homes, and we should be kicking gas out and moving to allelectric options for cooking, heating and hot water as fast as possible.

"I am a renter myself, so I am totally aware that this is easier said than done.

"I have very recently bought myself a cheap portable induction cooktop.

"And in the meantime, I'll work hard to lobby governments to help all Australians, no matter your income or housing situation, to get off gas.

"Interest-free loans are a great solution and will also incentivise landlords to swap gas appliances to electric ones," said Wilson.



JUMP OUT OF THE BOX

AWESOME FRANCHISE OPPORTUNITIES

✓ DEDICATED...

to best NIS price. No targets. No smoke and mirrors.

✓ DEDICATED...

4,000 sqm Distribution Centre with 1500+ ETHICAL and 20000+ FOS lines

✓ DEDICATED...

to our franchisees and partners. We are not owned by a wholesaler or supplier. Pharmacy owners profit. Not shareholders.









Beauty Wellness

Thu 30th March 2023 beauty@pharmacydaily.com.au

Editor's Choice: boosted serum with higher potency for skin

WHILE it may not feel as if we're in Autumn, it's good to prepare our skin for when the cold does eventually hit.

Ella Baché Hyaluronic Intensive Treatment Booster is a boosted serum enriched with five different molecular weights of hyaluronic acid, performing the most powerful restoration and protection above our everyday skincare for when our skin needs hydration most.

Boosted serums offer greater potency than your usual hydration go-to's, giving quick, transformative results and a salon-like experience at home for dehydrated skin.

Packed with more actives in

greater intensities than regular serums, this boosted serum can be used as a treatment for seven (or more) consecutive days each month to deliver extra hydration and firmness to your skin.

Ella Baché Hyaluronic Intensive Treatment Booster retails for \$99.

Created in France in 1936 by Madame Baché, Ella Baché is one of the oldest family-owned skincare companies in the world.

Known for its no-nonsense approach to skincare, Ella Baché believes in offering effective products that achieve results.

Notably, the sun care range was developed in Australia.



New skin care face

KIM Kardashian believes her eldest child will continue the family's three billion dollar legacy, as the reality star has filed for a variety of trademarks in North West's name - including skin care.

According to *The U.S. Sun*, North West has registered a trademark for products such as "non-medicated skin preparations, skin moisturisers, skin lotions, skin creams, skin cleansers, skin serums, facial oils, body oils, bath and shower gels, bubble bath, body powders, cosmetics, fragrances, and hair care preparations".



Return of Girlfriend

THE revival of *Girlfriend* magazine happened this month for a one-off print edition, featuring Taylor Swift on the cover, for the launch of the new Australian Amazon original series *Class of '07*.

The collector's print edition of *Girlfriend* will see the return of fan favourite sections such as 'How Embarrassment!' and 'Sex Ed', and features celebrity interviews with Emily Browning, Caitlin Stasey and Megan Smart from *Class of '07*.



Super blendable matte formula to lift face

MAYBELLINE New York Master Contour V-Face Duo Stick is a dual-ended cream stick that can be used to contour and highlight the face.

The easy to use, super blendable matte formula creates the illusion of structure and lift.

Apply the dark shade along the jawline and hollows of the cheeks, and apply the light shade to the high points of the face, such as the tops of cheeks and bridge of nose.

It is available in two shades: Light and



Medium, and retails for \$19.95.

The Maybelline product is useful in helping create a smooth base - just follow these steps:

Step 1: Apply concealer on the high points of the face and under the eyes.

Step 2: Apply cream contour underneath the cheekbones, jawline, sides of noses and temples.

Step 3: Apply cream blush heavily to the cheeks.

Step 4: Blend out your foundation with a fluffy powder brush.

Light-therapy mask

SAN LUEUR has launched its first Advance LED Light Therapy Facial Mask at an event at the Crown, Sydney.

The SAN LUEUR founder, Diana Shenouda welcomed invitees to an exclusive previewing event to discuss the brand's story and its vision for the future of beauty.

In line with the founder's ethos, the brand is cohesive between aesthetics and technology, which closely aligns with its latest launch.

The mask was developed to reduce the appearance of common skin concerns such as fine lines, dullness, blemishes, acne, and uneven skin tone, and uses a variety of different light technologies to have the skin looking and feeling its best.





DO YOU FOLLOW PHARMACY

DAILY ON FACEBOOK?



Click here to like us

Pharmacy Daily



Dispensary Corner

LEGAL action has been launched against a so-called "serial sperm donor" in the Netherlands, over claims he has increased the risk of accidental incest.

Jonathan Jacob Meijer is being sued by the country's Donorkind Foundation, after his donated sperm allegedly fathered more than 500 children - far more than guidelines allow which specify a maximum of 25 donations to prevent inbreeding.

A Dutch mother who gave birth to one of the babies in 2018 is the lead plaintiff, saying "if I had known he had already fathered more than 100 children I would never have chosen him".

The case is seeking a court order for Meijer to stop donating as well as provide details of all the clinics he has donated to, and to have all his stored sperm destroyed unless it's reserved for a woman who already has one of his children.

Despite already being on a blacklist for donations in the Netherlands, Donorkind claimed the 41-year-old continues to donate abroad.

BI posts strong results

BOEHRINGER Ingelheim
(BI) today reported a strong
performance in 2022, with research
and development investments
reaching €5b (A\$7.4b), or 21% of
net sales.

Net sales rose by a currencyadjusted 10.5% to €24.1b (A\$39.11b).

"2022 has shown that our longterm commitment to medical research is the right strategy.

"For some patient conditions that were until recently deemed difficult to treat, we have now found medical entities that can be true breakthroughs," said Hubertus von Baumbach, Chairman of the Board of Managing Directors.

"The acceleration of our broad pipeline demonstrates our commitment to transform the treatment of cardiovascular-renal diseases, inflammation, and respiratory diseases, mental health, oncology and retinal diseases."

Development of the pipeline progressed in 2022 with Boehringer Ingelheim receiving one Breakthrough Designation, three Fast Track Designations, and two Orphan Drug Designations from the FDA.

In the next seven years the company expects about 20

regulatory approvals in human pharma.

Throughout the current year, Boehringer Ingelheim expects to present additional data from its pipeline.

In 2022 operating income at Group level rose by 1.4% to €4.8b (A\$7.79b), while income after taxes was €3.2b (A\$5b).

"The strong commercial performance provides a solid base to finance our late-stage pipeline, mid-term growth opportunities, as well as further investments in new technologies.

"It will enable us to address future unmet patient needs," said Michael Schmelmer, Member of the Board of Managing Directors with responsibility for Finance & Group Functions.

The Human Pharma business achieved currency-adjusted net sales growth of 13.6% to €18.5b (A\$30b), driven by drugs Jardiance and Ofev.

Jardiance was the most significant growth and revenue contributor, with net sales of €5.8b (A\$9.4b) and a currency-adjusted growth of 39.1% in 2022.

Ofev generated net sales of €3.2b (A\$5b) and a currency-adjusted growth of 20.6% in 2022.

Opdivo listing

FROM Sat, 01 Apr Opdivo (nivolumab) will be listed on the PBS for resected oesophageal cancer (OC) or gastro-oesophageal junction cancer (GOJC) in patients who have received neoadjuvant chemoradiotherapy (CRT).

Despite the poor prognosis for oesophageal adenocarcinoma (the Australian five-year survival rate is only 23%), there are currently no adjuvant treatment options available for these patients in the neoadjuvant setting.


As the first adjuvant immunotherapy to be reimbursed for this patient group, Opdivo is fulfilling a significant, unmet clinical need.

The PBS listing is supported by positive data from the Phase 3 Checkmate 577 trial, in which Opdivo treatment in OC and GOJC patients following trimodality therapy (neoadjuvant CRT and complete surgical resection) doubled the disease-free survival of oesophageal and gastro-oesophageal cancer patients, compared to placebo (22.4 vs 11.0 months).

DRAW THE LINE...

when it comes to Digestive relief





Always read the label and follow the directions for use.

ne APOTEX trademark is under license. Apotex Pty Ltd Macquarie Park NSW 2113. ABN 52 096 916 148. Copyright © CONSUMER-000779. January 2023. All rights reserved



Check out our NEW website!



www.apohealth.com.au



www.pharmacydaily.com.au

Pharmacy Daily is part of the Business Publishing Group family of publications.

Pharmacy Daily is Australia's favourite pharmacy industry publication.

EDITORIAL

Editor in Chief and Publisher — Bruce Piper Associate Publisher — Anna Piper Editor — Jayamala Gupte Contributors — Adam Bishop, Myles Stedman, Janie Medbury,

Matthew Wai info@pharmacydaily.com.au

ADVERTISING AND MARKETING Sean Harrigan, Nicki Harford

advertising@pharmacydaily.com.au

BUSINESS MANAGER

Jenny Piper accounts@pharmacydaily.com.au

Suite 1, Level 2, 64 Talavera Rd Macquarie Park NSW 2113 Australia PO Box 1010 Epping NSW 1710 Australia Tel: 1300 799 220 (+61 2 8007 6760)

Sign up free at www.pharmacydaily.com.au



Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Bruce Piper.

A solution for every dispensary

We understand your patients always come first. We feel that's the same level of care you deserve. We're not just a supplier, we're a trusted partner, so we'll always work hard to ensure your needs are met.



There is a reason why over the past 15 years Willach has delivered over 1,000 dispensary solutions. We create spaces and systems that save time, optimise efficiency, reduce errors and improve medicine management, which maximises

returns and relieves some of the stress and pressure on owners and staff.

No matter the size of your pharmacy, contact us for a confidential discussion to explore the range of options available.





SOME BRANDS THINK MONEY TALKS...

Please bring back the other ones!!

These are inedible 🥮

Michaelle Molean

STATE OF STREET

Print Transference

They are foul! Glucojel Jelly Beans all the way

Ambar Ekselvedi

They are disgusting bring back the old ones

Tried them. Sorry not a fan 🥹

They are terrible. As a diabetic that buys jelly beans all the time they are awful

They are awful!!! Bring back the Glucogels

Glucogel taste heaps better than these tried them the other day and they are

These are awful. Was told they were the same jelly beans but with new package, misleading much!

WHAT!!??? They got rid of my jellybeans??? 😩 😩 😩 the world really is ending 😭 😭 😭

...we think customers do.





GLUCOJEL

The Original Pharmacy Jelly Bean



Australia's favourite jelly bean.
Only available at Australia's favourite pharmacies.